2017年3月30日 星期四
周光飚
周光飚
研究员(Professor Guang-Biao Zhou)

中国科学院动物研究所二级研究员,博士,博士生导师,国家杰出青年科学基金获得者。1993年毕业于广西医科大学临床医学系,2003年获上海交通大学医学院医学博士学位,2003年至2005年在中科院上海生命科学研究院从事博士后工作,2005年8月加入中科院广州生物医药与健康研究院,2009年7月加入中科院动物研究所。从事白血病与肺癌发病与治疗机理的研究,近年来聚焦空气污染与吸烟引起肺癌的机理与防治。在eLife、EBioMedicine、PNAS、Carcinogenesis、Oncotarget等期刊发表论文70多篇,被引用1800多篇次。目前担任中国医师协会临床精准医疗专业委员会委员、中国抗癌协会肿瘤转移专业委员会委员、中国转化医学联盟第一届理事会理事、中国病理生理学会实验血液学专业委员会委员,《Frontiers of Medicine》执行副主编,Austin Journal of Lung Cancer Research、International Journal of Hematology Research杂志编委,并评为Cancer Letters杂志的Outstanding reviewer。撰写的《关于减轻空气污染危害、切实保障国民健康的建议》被中办采用。

 

主要研究领域(Research Interests): 

主要研究肺癌的发病机理,特别是空气污染、吸烟引起肺癌的机理。从基因组、miRNAs、lncRNAs、炎症因子及其受体等层面研究肺癌发病机理。同时研究中药抗肺癌的作用与分子机制。

The environmental lung carcinogenesis, including how environmental pollutants induce genomic mutations, miRNA and lncRNA abnormalities and trigger chronic inflammation to promote cancer initiation and progression. And the effects and mechanisms of action of traditional Chinese medicine in treating lung cancer.

 

近2年代表性论文(selected publications,  * corresponding authors)

 

1.Wang GZ, Cheng X, Zhou B, Wen ZS, Huang YC, Chen HB, Li GF, Huang ZL, Zhou YC, Feng L, Wei MM, Qu LW, Cao Y, Zhou GB*. The chemokine CXCL13 in lung cancers associated with environmental polycyclic aromatic hydrocarbons pollution. eLIFE, 2015; 4: e09419.
 
2.Yu XJ, Yang MJ, Zhou B, Wang GZ, Huang YC, Wu LC, Cheng X, Wen ZS, Huang JY, Zhang YD, Gao XH, Li GF, He SW, Gu ZH, Ma L, Pan CM, Wang P, Chen HB, Hong ZP, Wang XL, Mao WJ, Jin XL, Kang H, Chen ST, Zhu YQ, Gu WY, Liu Z, Dong H, Tian LW, Chen SJ, Cao Y, Wang SY, Zhou GB*. Characterization of somatic mutations in air pollution-related lung cancer. EBioMedicine, 2015; 2:583-590.
 
3.Wang GZ, Cheng X, Li XC, Liu YQ, Wang XQ, Shi X, Wang ZY, Guo YQ, Wen ZS, Huang YC, Zhou GB*. Tobacco smoke induces production of chemokine CCL20 to promote lung cancer. Cancer Lett, 2015; 363:60-70
 
4.Pan HL, Wen ZS, Huang YC, Cheng X, Wang GZ, Zhou YC, Wang ZY, Guo YQ, Cao Y, Zhou GB*. Down-regulation of microRNA-144 in air pollution-related lung cancer. Sci Rep, 2015; 5:14331.
 
5.Liu YQ, Wang XL, Cheng X, Lu YZ, Wang GZ, Li XC, Zhang J, Wen ZS, Huang ZL, Gao QL, Yang LN, Cheng YX, Tao SC, Liu J, Zhou GB*. Skp1 in lung cancer: Clinical significance and therapeutic efficacy of its small molecule inhibitors. Oncotarget, 2015; 6:34953-34967.
 
6.Wang GZ, Liu YQ, Cheng X, Zhou GB*. Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents. Cancer Sci, 2015; 106:902-908.
 
7.Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W, Liu J, Zhou GB*. Cancerous inhibitor of PP2A (CIP2A) is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis, 2014; 35: 905-914..
 
8.Liu Z, Ma L, Wen ZS, Cheng YX, Zhou GB*. Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells. ACS Med ChemLett, 2014; 5: 113-118.